Fennec Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on February 4, 2019, covering events occurring on February 1, 2019. Fennec Pharmaceuticals Inc., a British Columbia corporation with principal offices in North Carolina, entered into a material definitive agreement to secure financing contingent upon regulatory approval for its drug candidate, PEDMARK.
Key Financial Metrics and Debt Structure
The filing details a new debt facility rather than historical operating results. Key terms include:
- Loan Amount: $12.5 million.
- Condition Precedent: Funds are available only upon New Drug Application (NDA) approval of PEDMARK by September 30, 2020.
- Interest Rate: Floating rate equal to the Prime Rate (currently 5.50%) plus 1.00%.
- Repayment Terms: Interest-only payments for the first 18 months, followed by monthly principal and interest payments. Maturity date is October 1, 2023.
- Prepayment Penalty: 1.00% of the outstanding principal if prepaid prior to maturity.
- Equity Component: The lender received a warrant to purchase up to 39,130 common shares at an exercise price of CAD$9.03 per share, exercisable for ten years.
- Liquidity Covenant: The company must maintain unrestricted cash and cash equivalents equal to or greater than three times its monthly cash burn amount.
- Collateral: First priority security interest in all assets excluding intellectual property (which is subject to a double negative pledge).
Material Changes
The primary material change is the execution of the Loan and Security Agreement with Bridge Bank (a division of Western Alliance Bank). The company paid a good faith deposit of $52,500 on December 21, 2018, which will be applied to bank expenses or refunded. This agreement represents a significant potential increase in debt capacity, contingent on the successful regulatory approval of PEDMARK.
Outlook, Risks, and Contingencies
Contingency: The $12.5 million loan is not guaranteed; funding is strictly conditional on the NDA approval of PEDMARK by September 30, 2020. If approval is not granted by this date, the loan facility will not be funded.
Risks and Events of Default: The agreement includes standard events of default that could trigger immediate repayment, including non-payment, failure to perform obligations, occurrence of a Material Adverse Event, seizure of material assets, or insolvency proceedings.
Management Commentary: Proceeds are designated for working capital and general business requirements. The filing does not provide specific revenue guidance or profit forecasts.
Investor Verification Checklist
- Verify the current status of the PEDMARK New Drug Application (NDA) and the likelihood of approval by the September 30, 2020 deadline.
- Confirm the company's current cash balance against the covenant requirement of maintaining three times the monthly cash burn.
- Review the valuation impact of the warrant issuance (39,130 shares at CAD$9.03) on existing shareholders.
- Assess the company's ability to service the debt (interest-only for 18 months) if the loan is funded, given the absence of reported revenue in this filing.
- Check for any subsequent filings regarding the status of the NDA or the funding of the loan.